Healthcare [ 11/13 ] | Biotechnology [ 92/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 6, 24 | -0.34 Decreased by -112.5% | -0.23 Decreased by -47.83% |
| Nov 9, 23 | -0.47 Decreased by -17.5% | -0.26 Decreased by -80.77% |
| Aug 10, 23 | -0.37 Increased by +53.75% | -0.26 Decreased by -42.31% |
| May 11, 23 | -0.18 Increased by +79.55% | -0.31 Increased by +41.94% |
| Mar 23, 23 | -0.16 Increased by +84.62% | -0.46 Increased by +65.22% |
| Nov 9, 22 | -0.4 Increased by +63.3% | -0.48 Increased by +16.67% |
| Aug 12, 22 | -0.8 Increased by +19.19% | -0.78 Decreased by -2.56% |
| May 12, 22 | -0.88 Increased by +12% | -0.83 Decreased by -6.02% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -42.37 M Decreased by -125.25% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -29.58 M Increased by +13.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 10.66 M Increased by +N/A% | -9.42 M Increased by +59.18% | Decreased by -88.33% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -5.82 M Increased by +78.58% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -18.81 M Increased by +33.81% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -34.33 M Decreased by -32.92% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -23.07 M Increased by +4.61% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -27.16 M Decreased by -14.65% | Decreased by N/A% Decreased by N/A% |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.